ELEVATED LEVELS OF AN ANGIOGENIC PEPTIDE, BASIC FIBROBLAST GROWTH-FACTOR, IN THE URINE OF PATIENTS WITH A WIDE SPECTRUM OF CANCERS
ELEVATED LEVELS OF AN ANGIOGENIC PEPTIDE, BASIC FIBROBLAST GROWTH-FACTOR, IN THE URINE OF PATIENTS WITH A WIDE SPECTRUM OF CANCERS
复制标题
DOI：
10.1093/jnci/86.5.356
复制
发表时间：
1994-03-02
期刊：
影响因子：
--
通讯作者：
FOLKMAN, J
中科院分区：
文献类型：
--
作者：
NGUYEN, M;WATANABE, H;FOLKMAN, J
背景资料：实验证据支持这样的假设，即血管的发育是实体瘤生长和转移的基础。血管生成肽碱性成纤维细胞生长因子（bFGF）的水平升高与膀胱癌的状态和疾病程度显著相关。目的：我们测量了膀胱以外器官癌症患者的bFGF水平，以确定是否伴随这些癌症的水平升高。研究方法：从950名患有各种实体瘤、白血病或淋巴瘤的患者以及87名健康志愿者和198名患有非癌症相关疾病的患者的对照组中收集尿液样品，使用酶生物测定法测量从尿液制备的样品中bFGF的水平。结果如下：男性对照组受试者的bFGF水平中位数为151 pg/g，女性对照组受试者的bFGF水平中位数为237 pg/g，合并的第百分位数为619 pg/g。除宫颈癌外，每种肿瘤患者尿液中bFGF水平均升高。例如，患有活动性局部癌症的患者的中位水平为312 pg/g。那些患有活动性转移性癌症的患者的中位水平为479 pg/g，第90百分位水平为14143 pg/g。在“升高”被定义为高于对照组的第90百分位数水平后，31%的局部活动性癌症患者和47%的转移性活动性癌症患者显示bFGF水平升高。在中位随访时间内，癌症患者的生存率为85%-88%，尿bFGF水平“正常”的患者为71%-72%。含义：我们的研究结果表明，尿液中的碱性成纤维细胞生长因子值得进一步评估其潜在的用途作为一个监测的治疗或作为一个预测结果，一旦癌症已被诊断。
Background: Experimental evidence supports the hypothesis that the development of blood vessels is fundamental to the growth and metastasis of solid tumors. Elevated levels of the angiogenic peptide basic fibroblast growth factor (bFGF) have been significantly correlated with the status and extent of disease in bladder cancer. Purpose: We measured the bFGF levels in patients with cancer in organs other than the bladder to determine whether elevated levels accompany these cancers. Methods: Urine samples were collected from 950 patients having a wide variety of solid tumors, leukemia, or lymphoma and from a control group of 87 healthy volunteers and 198 patients with noncancer-related diseases, Levels of bFGF in samples prepared from the urine were measured using an enzyme bioassay. Results: Male control subjects had a median bFGF level of 151 pg/g and female control subjects a median of 237 pg/g, with a combined ''th percentile of 619 pg/g. An elevated level of bFGF was found in the urine of some of the patients with every type of tumor studied except cervical carcinoma. For example, patients with active local cancers had a median level of 312 pg/g. Those with active, metastatic cancers had a median level of 479 pg/g and a 90th percentile level of 14143 pg/g. After ''elevated'' was defined to mean higher than the 90th percentile level for controls, 31% of patients with local active and 47% of patients with metastatic active cancers showed elevated bFGF levels. Survival among cancer patients at the median follow-up time was 85%-88% for those with ''normal'' and 71%-72% for those with ''elevated'' urine bFGF levels. Implications: Our results suggest that bFGF in urine deserves further evaluation of its potential use as a monitor of therapy or as a predictor of outcome once a cancer has been diagnosed.